Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Ailomics Therapeutics
AddedJul 2, 2026
UpdatedJul 2, 2026
Ailomics Therapeutics

Ailomics Therapeutics

Seed

Pioneering pharmaceutical R&D company with AI-powered multi-omics platform for novel target discovery in immune diseases and tumors.

HQ
Shanghai, Shanghai, CN
Founded
2022
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Ailomics Therapeutics is a Shanghai-based pharmaceutical R&D startup founded in 2022. It has developed a pioneering computational and experimental platform to analyze multi-omics data, discover novel targets, and advance first-in-class drug candidates.

The company focuses on treatments for immune diseases and tumors. It is a portfolio company of Qiming Venture Partners, which led its angel and seed funding rounds. Ailomics has become a resident company at Johnson & Johnson Innovation JLABS.

Ailomics Therapeutics - Similar Companies

Convexia logo

Convexia

convexia.bio

ImmunoMind logo

ImmunoMind

Stellaromics logo

Stellaromics

stellaromics.com

Aibios logo

Aibios

aibios.com

Triomics logo

Triomics

triomics.com

Alixia logo

Alixia

alixia.com

Pathos AI logo

Pathos AI

pathos.com

Aitia logo

Aitia

aitiabio.com

Complete Omics logo

Complete Omics

completeomics.com

BioAI Health logo

BioAI Health

bioaihealth.com

Omix.ai logo

Omix.ai

GEn1E Lifesciences logo

GEn1E Lifesciences

gen1e.com

Ordaos logo

Ordaos

ordaos.bio

Aikium logo

Aikium

aikium.com

Atomic AI logo

Atomic AI

atomic.ai

Ailomics Therapeutics - Quick Facts

Who are Ailomics Therapeutics' competitors?

Companies similar to Ailomics Therapeutics include Convexia, ImmunoMind, Stellaromics and Aibios.

When was Ailomics Therapeutics founded?

Ailomics Therapeutics was founded in 2022.

Where is Ailomics Therapeutics' headquarters located?

Ailomics Therapeutics' headquarters is located in Shanghai, Shanghai, CN.

When was Ailomics Therapeutics' last funding round?

Ailomics Therapeutics' most recent funding round was for $8.6M (USD) in May 2023.

How much has Ailomics Therapeutics raised to-date?

As of May 1, 2023, Ailomics Therapeutics has raised a total of $38.6M (USD).